AU2001282675A1 - A selectively-expressed epitope on the human cd38 molecule detected by a phage display library-derived human scfv antibody fragment - Google Patents

A selectively-expressed epitope on the human cd38 molecule detected by a phage display library-derived human scfv antibody fragment

Info

Publication number
AU2001282675A1
AU2001282675A1 AU2001282675A AU8267501A AU2001282675A1 AU 2001282675 A1 AU2001282675 A1 AU 2001282675A1 AU 2001282675 A AU2001282675 A AU 2001282675A AU 8267501 A AU8267501 A AU 8267501A AU 2001282675 A1 AU2001282675 A1 AU 2001282675A1
Authority
AU
Australia
Prior art keywords
human
selectively
antibody fragment
phage display
display library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282675A
Inventor
Lucia Cilenti
Ton Logtenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of AU2001282675A1 publication Critical patent/AU2001282675A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001282675A 2000-07-19 2001-07-19 A selectively-expressed epitope on the human cd38 molecule detected by a phage display library-derived human scfv antibody fragment Abandoned AU2001282675A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00202597 2000-07-19
EP00202597A EP1174440A1 (en) 2000-07-19 2000-07-19 A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
PCT/NL2001/000550 WO2002006347A1 (en) 2000-07-19 2001-07-19 A selectively-expressed epitope on the human cd38 molecule detected by a phage display library-derived human scfv antibody fragment

Publications (1)

Publication Number Publication Date
AU2001282675A1 true AU2001282675A1 (en) 2002-01-30

Family

ID=8171834

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282675A Abandoned AU2001282675A1 (en) 2000-07-19 2001-07-19 A selectively-expressed epitope on the human cd38 molecule detected by a phage display library-derived human scfv antibody fragment

Country Status (4)

Country Link
US (1) US20030211553A1 (en)
EP (1) EP1174440A1 (en)
AU (1) AU2001282675A1 (en)
WO (1) WO2002006347A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063819A2 (en) * 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
SI2511297T1 (en) * 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
DK1720907T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies as well as applications therefor
CN112480257A (en) 2005-03-23 2021-03-12 根马布股份公司 CD38 antibodies for the treatment of multiple myeloma
EP2799451A1 (en) * 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
RS56677B1 (en) 2005-10-12 2018-03-30 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP2039766A4 (en) * 2006-06-05 2010-06-16 Univ Hiroshima Immunocompetent cell having anti-cd38 antibody on its cell surface
DK2081595T3 (en) 2006-09-26 2019-07-15 Genmab As ANTI-CD38 PLUS CORTICOSTEROID PLUS A NON-CORTICOSTEROID KEMOTERAPEUTIKA FOR TUMOR TREATMENT
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
MX350540B (en) 2010-09-27 2017-09-08 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl.
KR102096224B1 (en) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 Polypeptide constructs and uses thereof
WO2014048921A1 (en) 2012-09-25 2014-04-03 Morphosys Ag Combinations and uses thereof
DK2914302T3 (en) 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
NZ713641A (en) 2013-04-29 2019-08-30 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US10675352B2 (en) * 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
MA40608A (en) 2014-09-09 2016-03-17 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of ac
CA2984464C (en) 2015-05-13 2023-10-10 Morphosys Ag Treatment for multiple myeloma (mm)
CN108136218B (en) 2015-05-20 2022-12-13 詹森生物科技公司 anti-CD 38 antibodies for the treatment of light chain amyloidosis and other CD 38-positive hematologic malignancies
KR102647100B1 (en) 2015-05-30 2024-03-13 몰레큘러 템플레이츠, 인코퍼레이션. Deimmunized Shiga toxin A subunit scaffolds and cell-targeting molecules comprising the same
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
AU2016350717B2 (en) 2015-11-03 2023-08-10 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2017149122A1 (en) 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma
MA50514A (en) 2017-10-31 2020-09-09 Janssen Biotech Inc HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
WO2019149743A1 (en) 2018-01-30 2019-08-08 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
TWI820270B (en) 2018-12-14 2023-11-01 德商莫菲西斯公司 Antibody formulations
CA3130132A1 (en) 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
WO2021002265A1 (en) * 2019-07-03 2021-01-07 Peptidream Inc. Cd38-binding agents and uses thereof
EP4169949A1 (en) * 2020-06-23 2023-04-26 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38 antibody and use thereof
JP2024503432A (en) 2021-01-14 2024-01-25 モルフォシス・アーゲー Use of anti-CD38 antibodies and anti-CD38 antibodies
TW202302642A (en) 2021-03-01 2023-01-16 德商莫菲西斯公司 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
TW202321303A (en) 2021-07-19 2023-06-01 德商莫菲西斯公司 Treatment of anti-pla2r-autoantibody-mediated membranous nephropathy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
AU4474497A (en) * 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target

Also Published As

Publication number Publication date
US20030211553A1 (en) 2003-11-13
WO2002006347A1 (en) 2002-01-24
EP1174440A1 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
AU2001282675A1 (en) A selectively-expressed epitope on the human cd38 molecule detected by a phage display library-derived human scfv antibody fragment
IL156030A0 (en) Humanized antibodies
EP1513879A4 (en) Synthetic antibody phage libraries
AU1174702A (en) Humanized anti-lt-beta-r antibodies
AU2002254570A1 (en) Epitope sequences
IL166244A0 (en) Super humanized antibodies
AU2002351623A1 (en) Streptococcus antigens
EP1264885A4 (en) Antibody library
HK1153649A1 (en) Therapeutic anti-il-1r1 monoclonal antibody il-1r1
AU2002365649A1 (en) Anti-dota antibody
IL136459A0 (en) Antibody library
AU2001290860A1 (en) Spas-1 cancer antigen
AU2002217213A1 (en) Human monoclonal antibody directed against the influenza virus or a fragment thereof
AU1598801A (en) HGF-SF monoclonal antibody combinations
AU2002221132A1 (en) Novel antibody
AU2003229799A1 (en) Novel humanized anti-vap-1 monoclonal antibody
AU5046700A (en) Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT
GB2367909B (en) 3D Retroflective screen
AU2001243435A1 (en) Intermediates useful for the synthesis of huperzine a
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin
AU2001251225A1 (en) Itinerary optimizer
AU2001272529A1 (en) Monoclonal antibody against human cathepsin w
AU2002217525A1 (en) Novel monoclonal antibody
AU2002223510A1 (en) Holographic projection screen
AU2002223408A1 (en) A monoclonal antibody, methods of producing it and the use thereof